189 related articles for article (PubMed ID: 25349303)
1. Utilization of the Eμ-Myc mouse to model heterogeneity of therapeutic response.
Rempel RE; Jiang X; Fullerton P; Tan TZ; Ye J; Lau JA; Mori S; Chi JT; Nevins JR; Friedman DR
Mol Cancer Ther; 2014 Dec; 13(12):3219-29. PubMed ID: 25349303
[TBL] [Abstract][Full Text] [Related]
2. Utilization of pathway signatures to reveal distinct types of B lymphoma in the Emicro-myc model and human diffuse large B-cell lymphoma.
Mori S; Rempel RE; Chang JT; Yao G; Lagoo AS; Potti A; Bild A; Nevins JR
Cancer Res; 2008 Oct; 68(20):8525-34. PubMed ID: 18922927
[TBL] [Abstract][Full Text] [Related]
3. Eμ-TCL1xMyc: A Novel Mouse Model for Concurrent CLL and B-Cell Lymphoma.
Lucas F; Rogers KA; Harrington BK; Pan A; Yu L; Breitbach J; Bundschuh R; Goettl VM; Hing ZA; Kanga P; Mantel R; Sampath D; Smith LL; Wasmuth R; White DK; Yan P; Byrd JC; Lapalombella R; Woyach JA
Clin Cancer Res; 2019 Oct; 25(20):6260-6273. PubMed ID: 31296529
[TBL] [Abstract][Full Text] [Related]
4. Genomic signatures in B-cell lymphoma: How can these improve precision in diagnosis and inform prognosis?
Iqbal J; Naushad H; Bi C; Yu J; Bouska A; Rohr J; Chao W; Fu K; Chan WC; Vose JM
Blood Rev; 2016 Mar; 30(2):73-88. PubMed ID: 26432520
[TBL] [Abstract][Full Text] [Related]
5. A biologic definition of Burkitt's lymphoma from transcriptional and genomic profiling.
Hummel M; Bentink S; Berger H; Klapper W; Wessendorf S; Barth TF; Bernd HW; Cogliatti SB; Dierlamm J; Feller AC; Hansmann ML; Haralambieva E; Harder L; Hasenclever D; Kühn M; Lenze D; Lichter P; Martin-Subero JI; Möller P; Müller-Hermelink HK; Ott G; Parwaresch RM; Pott C; Rosenwald A; Rosolowski M; Schwaenen C; Stürzenhofecker B; Szczepanowski M; Trautmann H; Wacker HH; Spang R; Loeffler M; Trümper L; Stein H; Siebert R;
N Engl J Med; 2006 Jun; 354(23):2419-30. PubMed ID: 16760442
[TBL] [Abstract][Full Text] [Related]
6. A new model of LMP1-MYC interaction in B cell lymphoma.
Ontiveros EP; Halwani A; Stunz LL; Kamberos N; Olivier AK; Janz S; Bishop GA
Leuk Lymphoma; 2014 Dec; 55(12):2917-23. PubMed ID: 24605938
[TBL] [Abstract][Full Text] [Related]
7. [B-cell lymphomas with concurrent myc and bcl-2/IgH or bcl-6 translocations].
Luo DL; Liu YH; Zhang F; Xu FP; Yan LX; Chen J; Xu J; Luo XL; Zhuang HG
Zhonghua Bing Li Xue Za Zhi; 2013 Sep; 42(9):584-8. PubMed ID: 24314242
[TBL] [Abstract][Full Text] [Related]
8. Bptf determines oncogenic addiction in aggressive B-cell lymphomas.
Richart L; Felipe I; Delgado P; Andrés MP; Prieto J; Pozo ND; García JF; Piris MA; Ramiro A; Real FX
Oncogene; 2020 Jun; 39(25):4884-4895. PubMed ID: 32451433
[TBL] [Abstract][Full Text] [Related]
9. Insertion of c-Myc into Igh induces B-cell and plasma-cell neoplasms in mice.
Park SS; Kim JS; Tessarollo L; Owens JD; Peng L; Han SS; Tae Chung S; Torrey TA; Cheung WC; Polakiewicz RD; McNeil N; Ried T; Mushinski JF; Morse HC; Janz S
Cancer Res; 2005 Feb; 65(4):1306-15. PubMed ID: 15735016
[TBL] [Abstract][Full Text] [Related]
10. Sole rearrangement but not amplification of MYC is associated with a poor prognosis in patients with diffuse large B cell lymphoma and B cell lymphoma unclassifiable.
Landsburg DJ; Falkiewicz MK; Petrich AM; Chu BA; Behdad A; Li S; Medeiros LJ; Cassaday RD; Reddy NM; Bast MA; Vose JM; Kruczek KR; Smith SE; Patel P; Hernandez-Ilizaliturri F; Karmali R; Rajguru S; Yang DT; Maly JJ; Blum KA; Zhao W; Vanslambrouck C; Nabhan C
Br J Haematol; 2016 Nov; 175(4):631-640. PubMed ID: 27469075
[TBL] [Abstract][Full Text] [Related]
11. Prognostic value of MYC rearrangement in cases of B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and Burkitt lymphoma.
Lin P; Dickason TJ; Fayad LE; Lennon PA; Hu P; Garcia M; Routbort MJ; Miranda R; Wang X; Qiao W; Medeiros LJ
Cancer; 2012 Mar; 118(6):1566-73. PubMed ID: 21882178
[TBL] [Abstract][Full Text] [Related]
12. Deregulated expression of HDAC9 in B cells promotes development of lymphoproliferative disease and lymphoma in mice.
Gil VS; Bhagat G; Howell L; Zhang J; Kim CH; Stengel S; Vega F; Zelent A; Petrie K
Dis Model Mech; 2016 Dec; 9(12):1483-1495. PubMed ID: 27799148
[TBL] [Abstract][Full Text] [Related]
13. AID and RAG1 do not contribute to lymphomagenesis in Emu c-myc transgenic mice.
Nepal RM; Zaheen A; Basit W; Li L; Berger SA; Martin A
Oncogene; 2008 Aug; 27(34):4752-6. PubMed ID: 18408759
[TBL] [Abstract][Full Text] [Related]
14. Allele-specific loss or imbalance of chromosomes 9, 15, and 16 in B-cell tumors from interspecific F1 hybrid mice carrying Emu-c-myc or N-myc transgenes.
Linardopoulos S; Silva S; Klein G; Balmain A
Int J Cancer; 2000 Dec; 88(6):920-7. PubMed ID: 11093815
[TBL] [Abstract][Full Text] [Related]
15. Molecular classification of MYC-driven B-cell lymphomas by targeted gene expression profiling of fixed biopsy specimens.
Carey CD; Gusenleitner D; Chapuy B; Kovach AE; Kluk MJ; Sun HH; Crossland RE; Bacon CM; Rand V; Dal Cin P; Le LP; Neuberg D; Sohani AR; Shipp MA; Monti S; Rodig SJ
J Mol Diagn; 2015 Jan; 17(1):19-30. PubMed ID: 25468432
[TBL] [Abstract][Full Text] [Related]
16. Non-Hodgkin's B-cell lymphoma: advances in molecular strategies targeting drug resistance.
Maxwell SA; Mousavi-Fard S
Exp Biol Med (Maywood); 2013 Sep; 238(9):971-90. PubMed ID: 23986223
[TBL] [Abstract][Full Text] [Related]
17. [Analysis of genomic copy number alterations of malignant lymphomas and its application for diagnosis].
Tagawa H
Gan To Kagaku Ryoho; 2007 Jul; 34(7):975-82. PubMed ID: 17637530
[TBL] [Abstract][Full Text] [Related]
18. CDK4 deficiency promotes genomic instability and enhances Myc-driven lymphomagenesis.
Lu Y; Wu Y; Feng X; Shen R; Wang JH; Fallahi M; Li W; Yang C; Hankey W; Zhao W; Ganju RK; Li MO; Cleveland JL; Zou X
J Clin Invest; 2014 Apr; 124(4):1672-84. PubMed ID: 24614102
[TBL] [Abstract][Full Text] [Related]
19. BET Inhibition Induces Apoptosis in Aggressive B-Cell Lymphoma via Epigenetic Regulation of BCL-2 Family Members.
Hogg SJ; Newbold A; Vervoort SJ; Cluse LA; Martin BP; Gregory GP; Lefebure M; Vidacs E; Tothill RW; Bradner JE; Shortt J; Johnstone RW
Mol Cancer Ther; 2016 Sep; 15(9):2030-41. PubMed ID: 27406984
[TBL] [Abstract][Full Text] [Related]
20. MYC deregulation in lymphoid tumors: molecular mechanisms, clinical consequences and therapeutic implications.
Sewastianik T; Prochorec-Sobieszek M; Chapuy B; Juszczyński P
Biochim Biophys Acta; 2014 Dec; 1846(2):457-67. PubMed ID: 25199984
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
